Switching of Hormone Therapies in Breast Cancer Women.
Luana Moreira de MedeirosRebeca StahlschmidtAmanda Canato FerraciniCinthia Madeira de SouzaCassia Raquel Teatin JuliatoPriscila Gava MazzolaPublished in: Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia (2021)
The present study demonstrated a low rate of HT switch of tamoxifen to anastrozole. Among the reasons for changing therapy, the most common was disease progression, which includes cancer recurrence, metastasis or increased tumor. Side effects were second; furthermore, age and comorbidities are risk factors for side effects.